procarbazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2272	671-16-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: procarbazine ibenzmethyzine procarbazine hydrochloride procarbazine HCl	An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. Molecular weight: 221.30 Formula: C12H19N3O CLOGP: -0.08 LIPINSKI: 0 HAC: 4 HDO: 3 TPSA: 53.16 ALOGS: -2.99 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

procarbazine
ibenzmethyzine
procarbazine hydrochloride
procarbazine HCl

An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.

Molecular weight: 221.30
Formula: C12H19N3O
CLOGP: -0.08
LIPINSKI: 0
HAC: 4
HDO: 3
TPSA: 53.16
ALOGS: -2.99
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	27.11 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
S (Water solubility)	100 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
July 22, 1969	FDA	SIGMA TAU

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatitis B reactivation	258.80	35.98	56	4089	3081	63481796
Nausea	149.56	35.98	226	3919	854245	62630632
Acute hepatic failure	141.87	35.98	51	4094	18276	63466601
Full blood count abnormal	114.76	35.98	51	4094	31666	63453211
Neutropenia	78.04	35.98	75	4070	174930	63309947
Tissue infiltration	73.58	35.98	15	4130	614	63484263
Basal ganglion degeneration	72.45	35.98	14	4131	434	63484443
Fatigue	63.78	35.98	162	3983	887866	62597011
Uterine enlargement	63.10	35.98	15	4130	1253	63483624
Necrotising gastritis	58.54	35.98	9	4136	67	63484810
Maternal exposure before pregnancy	58.19	35.98	21	4124	7582	63477295
Inguinal hernia	56.26	35.98	15	4130	1992	63482885
Disease progression	55.38	35.98	53	4092	122705	63362172
Anaesthesia	54.60	35.98	11	4134	424	63484453
Psychogenic seizure	53.92	35.98	14	4131	1678	63483199
Hepatocellular injury	48.17	35.98	27	4118	27354	63457523
Neurological decompensation	47.77	35.98	14	4131	2624	63482253
Hepatic cytolysis	46.93	35.98	22	4123	15385	63469492
Platelet count decreased	46.52	35.98	47	4098	116075	63368802
Monoplegia	45.10	35.98	14	4131	3187	63481690
Hypochromic anaemia	42.75	35.98	12	4133	1930	63482947
Psychiatric decompensation	41.79	35.98	11	4134	1390	63483487
Dysaesthesia	40.48	35.98	14	4131	4464	63480413
Persecutory delusion	38.45	35.98	12	4133	2778	63482099
Klebsiella infection	38.25	35.98	16	4129	8550	63476327
Thrombocytopenia	36.39	35.98	47	4098	151110	63333767

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute myeloid leukaemia	276.95	30.94	98	4129	18172	34934532
Nausea	213.27	30.94	231	3996	339677	34613027
Second primary malignancy	181.60	30.94	58	4169	7828	34944876
Fatigue	136.27	30.94	193	4034	370460	34582244
Malignant transformation	123.57	30.94	27	4200	824	34951880
Myelodysplastic syndrome	115.39	30.94	53	4174	19155	34933549
Blood stem cell transplant failure	87.67	30.94	18	4209	404	34952300
Neutropenia	86.04	30.94	100	4127	156678	34796026
Full blood count abnormal	80.31	30.94	41	4186	18627	34934077
Myositis	62.25	30.94	30	4197	12040	34940664
Hepatocellular injury	60.26	30.94	36	4191	22175	34930529
Transformation to acute myeloid leukaemia	46.36	30.94	12	4215	762	34951942
Malignant neoplasm progression	44.55	30.94	54	4173	87992	34864712
Angiodysplasia	42.58	30.94	11	4216	693	34952011
Disease progression	40.25	30.94	57	4170	108020	34844684
Premature ageing	38.52	30.94	7	4220	80	34952624
Leukoencephalopathy	36.27	30.94	15	4212	4200	34948504
Heart disease congenital	35.18	30.94	11	4216	1379	34951325
Hepatic cancer	35.05	30.94	18	4209	8257	34944447
Herpes simplex encephalitis	34.22	30.94	8	4219	332	34952372
Platelet count decreased	33.09	30.94	55	4172	119662	34833042
Urticaria	31.10	30.94	38	4189	62339	34890365
Acute promyelocytic leukaemia	31.07	30.94	8	4219	497	34952207

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute myeloid leukaemia	280.31	29.27	102	6305	30783	79707198
Second primary malignancy	214.85	29.27	69	6338	14281	79723700
Neutropenia	180.04	29.27	163	6244	287547	79450434
Myelodysplastic syndrome	131.77	29.27	59	6348	30242	79707739
Malignant transformation	119.29	29.27	26	6381	1192	79736789
Hepatocellular injury	114.81	29.27	62	6345	47531	79690450
Disease progression	91.30	29.27	92	6315	184270	79553711
Malignant neoplasm progression	86.59	29.27	78	6329	135912	79602069
Blood stem cell transplant failure	72.89	29.27	15	6392	520	79737461
Hepatic cytolysis	70.02	29.27	37	6370	27114	79710867
Febrile neutropenia	66.34	29.27	87	6320	230912	79507069
Myositis	63.68	29.27	31	6376	19137	79718844
Necrotising gastritis	63.02	29.27	10	6397	74	79737907
Tissue infiltration	58.00	29.27	13	6394	678	79737303
Basal ganglion degeneration	57.76	29.27	12	6395	436	79737545
Uterine enlargement	54.46	29.27	13	6394	895	79737086
Leukoencephalopathy	49.60	29.27	20	6387	7909	79730072
Febrile bone marrow aplasia	49.16	29.27	23	6384	12997	79724984
Full blood count abnormal	46.79	29.27	33	6374	40441	79697540
Product use in unapproved indication	46.73	29.27	77	6330	250282	79487699
Thrombocytopenia	46.08	29.27	79	6328	265180	79472801
Psychogenic seizure	44.74	29.27	13	6394	1918	79736063
Anaesthesia	44.70	29.27	10	6397	517	79737464
Bone marrow failure	44.18	29.27	35	6372	51072	79686909
Hepatitis B reactivation	43.78	29.27	17	6390	6091	79731890
Angiodysplasia	42.14	29.27	11	6396	1091	79736890
Premature ageing	40.91	29.27	7	6400	86	79737895
Neoplasm progression	39.62	29.27	33	6374	51649	79686332
Pneumocystis jirovecii pneumonia	38.73	29.27	27	6380	32481	79705500
Pancytopenia	37.89	29.27	56	6351	165689	79572292
Dysaesthesia	37.44	29.27	15	6392	5833	79732148
Peripheral sensory neuropathy	37.14	29.27	19	6388	13014	79724967
Monoplegia	35.53	29.27	13	6394	3958	79734023
Neurological decompensation	35.46	29.27	14	6393	5239	79732742
Osteonecrosis	35.12	29.27	25	6382	31070	79706911
Hepatic cancer	34.88	29.27	17	6390	10512	79727469
Haematotoxicity	34.02	29.27	19	6388	15500	79722481
Benign prostatic hyperplasia	33.30	29.27	17	6390	11595	79726386
Herpes simplex encephalitis	31.32	29.27	8	6399	728	79737253
Intervertebral disc disorder	29.59	29.27	12	6395	4813	79733168
Persecutory delusion	29.39	29.27	12	6395	4897	79733084
Inguinal hernia	29.35	29.27	13	6394	6475	79731506

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01XB01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Methylhydrazines
FDA MoA	N0000000236	Alkylating Activity
FDA EPC	N0000175558	Alkylating Drug
MeSH PA	D000970	Antineoplastic Agents
CHEBI has role	CHEBI:35610	antineoplastic agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hodgkin's disease	indication	118599009
Astrocytoma, anaplastic	off-label use	55353007	DOID:3078
Diffuse non-Hodgkin's lymphoma, large cell	off-label use	109969005
Polycythemia vera	off-label use	109992005
Mycosis fungoides	off-label use	118618005
Glioblastoma multiforme of brain	off-label use	276828006	DOID:3073
Malignant neoplasm of brain	off-label use	428061005	DOID:1319
Mycosis	contraindication	3218000	DOID:1564
Alcoholism	contraindication	7200002
Viral disease	contraindication	34014006	DOID:934
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Blood coagulation disorder	contraindication	64779008	DOID:1247
Leukopenia	contraindication	84828003	DOID:615
Bacterial infectious disease	contraindication	87628006
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Peripheral nerve disease	contraindication	302226006
Bone marrow depression	contraindication	307762000
Breastfeeding (mother)	contraindication	413712001
Smokes tobacco daily	contraindication	449868002
Protozoal Infection	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.29	acidic
pKa2	7.0	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4019906	VUID
N0000147991	NUI
D00478	KEGG_DRUG
366-70-1	SECONDARY_CAS_RN
4017789	VANDF
4019906	VANDF
C0033223	UMLSCUI
CHEBI:71417	CHEBI
CHEMBL1321	ChEMBL_ID
DB01168	DRUGBANK_ID
D011344	MESH_DESCRIPTOR_UI
4915	PUBCHEM_CID
7278	IUPHAR_LIGAND_ID
2147	INN_ID
35S93Y190K	UNII
66925	RXNORM
5360	MMSL
d00354	MMSL
002672	NDDF
004827	NDDF
10174003	SNOMEDCT_US
387474003	SNOMEDCT_US
81583003	SNOMEDCT_US
CHEMBL1200410	ChEMBL_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Matulane	HUMAN PRESCRIPTION DRUG LABEL	1	54482-054	CAPSULE	50 mg	ORAL	NDA	23 sections
Matulane	HUMAN PRESCRIPTION DRUG LABEL	1	54482-054	CAPSULE	50 mg	ORAL	NDA	23 sections